Form 4: ORIC Director Granted Stock Options

Oric Pharmaceuticals Director Steven L. Hoerter was granted 40,000 stock options with an exercise price of $8.17, vesting over 12 months.

Summary

• Steven L. Hoerter, a Director of Oric Pharmaceuticals, Inc. (ORIC), was granted 40,000 stock options.
• The options have an exercise price of $8.17 per share.
• The transaction date for this grant was January 2, 2026.
• The options will vest at a rate of 1/12th of the shares on each one-month anniversary of January 2, 2026.
• The expiration date for these stock options is January 1, 2036.
• Following this transaction, Mr. Hoerter beneficially owns 40,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is generally a positive event, indicating continued alignment of management interests with shareholder value creation, though it is a routine compensation disclosure.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term company performance.
• The options have a 10-year expiration date, providing a long-term incentive horizon.

Future Outlook

The filing details a future vesting schedule for the granted stock options, with shares vesting monthly starting from January 2, 2026, over a 12-month period.

Industry Context

This transaction represents a routine equity compensation event for a director in the biotechnology or pharmaceutical industry, common for aligning executive and board member interests with long-term company performance.

Stakeholder Impact

• Shareholders: The grant of options to a director can enhance alignment between the director's financial incentives and the company's long-term stock performance, potentially benefiting shareholders.

Next Steps

• The stock options will vest monthly over a 12-month period, starting from January 2, 2026.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Oric Pharmaceuticals. While it indicates continued alignment of interests, it is not a catalyst for a change in recommendation based solely on this disclosure.

Keywords

ORIC, Oric Pharmaceuticals, stock option, equity compensation, insider transaction, director, Form 4